The clinical impact of single inhaler therapy in asthma

Clinical and Experimental Allergy

Volumn 42, Issue 7, 2012, Pages 1006-1013

  Czarnecka, K ^a,b   Chapman, K R ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Asthma; Budesonide; Control; Formoterol; Inhaled corticosteroid; Long acting beta2 agonist

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; TERBUTALINE;

ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; EOSINOPHIL COUNT; HUMAN; INFLAMMATION; LUNG BIOPSY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SPUTUM; SYSTEMATIC REVIEW; TREATMENT DURATION;

ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 84862574045     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03928.x     Document Type: Review

References (50)

1. Haahtela T, Jarvinen M, Kava T et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma [see comments]. N Engl J Med 1991; 325:388-92.
2. Haahtela T, Klaukka T. Societal and health care benefits of early use of inhaled steroids. Thorax 1998; 53:1005-6.
3. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group. Am J Respir Crit Care Med 1999; 159:1043-51.
4. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
5. Boulet LP, Becker A, Bçrubç D, Beveridge R, Ernst P, Canadian Asthma CG. Canadian asthma consensus report, 1999. Can Med Assoc J 1999; 161:S1-S5.
6. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-24.
7. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170:836-44.
8. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [see comments] [published erratum appears in N Engl J Med 1998 Jan 8;338(2):139]. N Engl J Med 1997;337:1405-11.
9. Lemanske RFJr, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Eng J Med 2010; 362:975-85.
10. Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 2010; 65:747-52.
11. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2009; CD007313. DOI: 10.1002/14651858.CD007313.pub2.
12. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009; CD007085. DOI: 10.1002/14651858.CD007085.pub2.
13. Chapman KR, Boulet LP, Rea RM, Franssen E. Sub-optimal asthma control: prevalence, detection and consequences in primary practice. Eur Respir J 2007;xx:09031936.
14. Chapman KR, Ernst P, Grenville A, Dewland P, Zimmerman S. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J 2001; 8(Suppl. A):35A-40A.
15. Vogelmeier C, D'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26:819-28.
16. Bousquet J, Boulet LP, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101:2437-46.
17. Sears MR, Boulet LP, Laviolette M et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008; 31:982-9.
18. Anon. Clinical Study Report Synopsis:A comparison of the efficacy of Symbicortr SMART¶ (Symbicort)Turbuhalerr 160/4.5 ç g 1 inhalation bi.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre, 26 weeks study; 2008. Available at (accessed 12 September 2008).
19. Anon. Synopsis: A comparison of Symbicort Single inhaler Therapy (Symbicort Turbohaler 160/4.5 Êg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multi-centre study (SALTO); 2008. Available at: (accessed 7 December 2011).
20. O'Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129-36.
21. Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20:1403-18.
22. Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129:246-56.
23. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of thedose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-8.
24. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368:744-53.
25. Global Initiative for A. Global strategy for asthma management and prevention 2008. Available at: (accessed 19 June 2011).
26. Reddel HK, Taylor DR, Bateman ED et al. An official American thoracic society/European respiratory society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99.
27. Bateman ED, Reddel HK, Eriksson G et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010;125:600-8, 8.
28. Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61:725-36.
29. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study. Eur Respir J 2000; 16:802-7.
30. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002; 110:58-64.
31. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31:320-5.
32. Fitzgerald JM, Boulet LP, McIvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains suboptimal: the reality of asthma control (TRAC) study. Can Respir J 2006; 13:253-9.
33. Australia NAC. Asthma management handbook 2006. Melbourne: National Asthma Council Australia Ltd; 2006.
34. [No author listed]. British guideline on the management of asthma - a national clinical guideline - introduction. Thorax 2003;58:i1-i94.
35. Becker A, Lemiere C, Berube D et al. Summary of recommendations from the Canadian asthma consensus guidelines, 2003. CMAJ: Can Med Assoc J 2005; 173:S3-11.
36. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004; 59:94-9.
37. Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? Arch Pediatr Adolesc Med 2008; 162:157-63.
38. Gibson PG, Powell H, Coughlan J et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003; CD001117. DOI: 10.1002/14651858.CD001117.
39. Szczepanski R, Konning J, Lob-Corzilius T, von Schlippe A, Theiling S. Analysis of the current status of asthma education for children and adolescents in German-speaking countries. Pneumologie 1993; 47:583-7.
40. Runge C, Lecheler J, Horn M, Tews JT, Schaefer M. Outcomes of a web-based patient education program for asthmatic children and adolescents. Chest 2006; 129:581-93.
41. Adachi M, Morikawa A, Ishihara K. Asthma insights & reality in Japan (AIRJ). Arerugi 2002; 51:411-20.
42. Lai CKW, De Guia TS, Kim YY et al. Asthma control in the Asia-Pacific region: the asthma insights and reality in Asia-Pacific study. J Allergy Clin Immunol 2003; 111:263-8.
43. Boyter AC, Ford NH, Zlotos L. Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the UK. Respir Med 2011; 105:864-8.
44. Rubinfeld AR, Pain MC. Perception of asthma. Lancet 1976; 1:882-4.
45. Rushford N, Tiller JW, Pain MC. Perception of natural fluctuations in peak flow in asthma: clinical severity and psychological correlates. J Asthma 1998; 35:251-9.
46. Burdon JG, Juniper EF, Killian KJ, Hargreave FE, Campbell EJ. The perception of breathlessness in asthma. Am Rev Respir Dis 1982; 126:825-8.
47. Mawhinney H, Spector SL, Heitjan D, Kinsman RA, Dirks JF, Pines I. As-needed medication use in asthma usage patterns and patient characteristics. J Asthma 1993; 30:61-71.
48. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta- agonists with corticosteroids improve compliance? Eur Respir J 1994; 7:504-9.
49. Dompeling E, van Grunsven PM, Van Schayck CP, Folgering H, Molema J, Van Weel C. Treatment with inhaled steroids in asthma and chronic bronchitis: longterm compliance and inhaler technique. Fam Pract 1992; 9:161-6.
50. Pavord ID, Jeffery PK, Qiu Y et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009;123:1083-9, 9.